Xenon Pharmaceuticals (XENE) sets June 2, 2026 annual shareholder meeting and April 7 record date

Rhea-AI Filing Summary

Xenon Pharmaceuticals Inc. outlined key details for its 2026 annual meeting of shareholders. The meeting is scheduled for June 2, 2026, with a record date for notice and voting of April 7, 2026, which is also the beneficial ownership determination date.

Holders of Xenon common shares are entitled to receive notice of and vote at the meeting. The company will not mail materials directly to non-objecting beneficial owners but will pay for distribution to objecting beneficial owners. Xenon is using notice-and-access for both registered and non-registered investors, and the related information was also submitted through a SEDAR+ filing furnished as Exhibit 99.1.

0001582313false00015823132026-03-132026-03-13

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 13, 2026

XENON PHARMACEUTICALS INC.

(Exact name of Registrant as Specified in Its Charter)

Canada	001-36687	98-0661854
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)
3650 Gilmore Way Burnaby, British Columbia, Canada		V5G 4W8
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: (604) 484-3300

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Shares, without par value		XENE		The Nasdaq Stock Market LLC (The Nasdaq Global Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events

On March 13, 2026, Xenon Pharmaceuticals Inc. announced the meeting, record date and certain other information relating to its 2026 annual meeting of shareholders pursuant to a filing submitted to the System for Electronic Document Analysis and Retrieval in Canada.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits.

Pursuant to the rules and regulations of the Securities and Exchange Commission, the attached exhibit is deemed to have been furnished to, but not filed with, the Securities and Exchange Commission:

Exhibit Number	Description
99.1	SEDAR+ filing submitted March 13, 2026.
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 

		XENON PHARMACEUTICALS INC.
Date: March 13, 2026		By:	/s/ Thomas P. Kelly
			Thomas P. Kelly
			Chief Financial Officer

March 13, 2026

Alberta Securities Commission

British Columbia Securities Commission

Ontario Securities Commission

RE: Xenon Pharmaceuticals Inc.

Pursuant to a request from the above-mentioned reporting issuer, we wish to advise you of the following information in connection with its Annual Meeting of Shareholders:

Date of meeting:	June 2, 2026
Record date for notice:	April 7, 2026
Record date for voting:	April 7, 2026
Beneficial ownership determination date:	April 7, 2026
Securities entitled to notice:	Common Shares
Securities entitled to vote:	Common Shares
Issuer mailing directly to non-objecting beneficial owners:	No
Issuer will pay for objecting beneficial owner material distribution:	Yes
Issuer using notice-and-access for registered investors:	Yes
Issuer using notice-and-access for non-registered investors:	Yes
Notice-and-access stratification criteria:	N/A

Thank you!

Shelby Behr
Client Success Manager
+1 (919) 410-4412 W
shelby.behr@betanxt.com
Mediant, a BetaNXT business

FAQ

When is Xenon Pharmaceuticals Inc. (XENE) holding its 2026 annual meeting of shareholders?

Xenon Pharmaceuticals will hold its 2026 annual meeting of shareholders on June 2, 2026. This is the formal date when common shareholders can vote on company matters, using eligibility based on the established record and ownership determination dates.

What is the record date for Xenon Pharmaceuticals (XENE) 2026 annual meeting?

The record date for notice and voting at Xenon Pharmaceuticals’ 2026 annual meeting is April 7, 2026. Shareholders who own common shares on that date are entitled to receive meeting materials and vote at the June 2, 2026 meeting.

Which securities can vote at Xenon Pharmaceuticals (XENE) 2026 annual meeting?

At Xenon Pharmaceuticals’ 2026 annual meeting, common shares are entitled to both notice and voting rights. The beneficial ownership determination date is April 7, 2026, so holders of common shares on that date may participate in the shareholder vote.

Is Xenon Pharmaceuticals (XENE) using notice-and-access for its 2026 annual meeting materials?

Yes. Xenon Pharmaceuticals is using notice-and-access for both registered and non-registered investors. This means shareholders receive a notice explaining how to access proxy and meeting materials electronically, rather than receiving full paper packages by default.

Will Xenon Pharmaceuticals (XENE) pay for distribution of materials to objecting beneficial owners?

Yes. Xenon Pharmaceuticals will pay for material distribution to objecting beneficial owners. However, the issuer will not mail directly to non-objecting beneficial owners, relying instead on intermediaries and its notice-and-access approach to deliver meeting information.

How did Xenon Pharmaceuticals (XENE) communicate its 2026 annual meeting details in Canada?

Xenon Pharmaceuticals communicated its 2026 annual meeting, record date, and related details through a SEDAR+ submission. This Canadian electronic filing is referenced in the U.S. disclosure and furnished as Exhibit 99.1 to provide consistent meeting information across jurisdictions.

Filing Exhibits & Attachments

2 documents

Press Releases

• EX-99.1 EX-99.1 18.2 KB

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 29.9 KB